The Institute for Medical Research hosted a Scientific Seminar with Miloš Brkušanin, Assistant Professor at the Faculty of Biology, on spinal muscular atrophy (SMA) and new strategies for its treatment.
In his lecture, “Newborn Screening and Personalized Therapy: A New Paradigm in Treating SMA,” Brkušanin underscored that without early intervention, SMA remains the leading genetic cause of infant mortality, with any delay in diagnosis carrying a high risk of fatal outcomes.
He emphasized that Serbia’s national newborn screening program and the work of the expert SMA committee are reshaping practice, shifting from a classical, symptom-based approach toward preventive and targeted treatment. Timely use of genetically designed therapies, he noted, offers children the chance for normal development and an improved quality of life.
